Skip to main content

Table 1 Baseline characteristics of ARAS and non-ARAS patients

From: Lipoprotein (a) as a residual risk factor for atherosclerotic renal artery stenosis in hypertensive patients: a hospital-based cross-sectional study

  TOTAL
N = 170
ARAS
N = 85
Non-ARAS
N = 85
P value
Age (year) 69.00 (62.00 – 75.00) 72.00 (64.00 – 76.00) 68.00 (61.00 – 74.00) 0.062
Male 110 (64.71) 57 (67.06) 53 (62.35) 0.521
Body Mass Index (kg/m2) 23.93 (22.15 – 25.82) 23.73 (21.64 – 25.78) 24.03 (22.59 – 26.12) 0.214
Current smoking 51 (30.00) 30 (35.29) 21 (24.71) 0.132
Systolic blood pressure (mmHg) 147.08 ± 24.01 151.72 ± 26.66 142.44 ± 20.14 0.011
Diastolic blood pressure (mmHg) 77.64 ± 11.57 77.79 ± 11.58 77.48 ± 11.63 0.864
Diabetes mellitus 68 (40.00) 33 (38.82) 35 (41.18) 0.754
Coronary artery disease 139 (81.76) 63 (74.12) 76 (89.41) 0.010
Peripheral arterial disease 43 (25.29) 28 (32.94) 15 (17.65) 0.022
Antihypertensive 166 (97.65) 83 (97.65) 83 (97.65) 1.000*
 ACEIs/ARBs 134 (78.82) 62 (72.94) 72 (84.71) 0.060
 β-receptor blockers 121 (71.18) 59 (69.41) 62 (72.94) 0.611
 Calcium channel blockers 84 (49.41) 51 (60.00) 33 (38.82) 0.006
 Diuretics 47 (27.65) 23 (27.06) 24 (28.24) 0.864
 α-receptor blockers 11 (6.47) 9 (10.59) 2 (2.35) 0.057*
Statin 10 (5.88) 4 (4.71) 6 (7.06) 0.746*
  1. Abbreviations: ACEIs Angiotensin converting enzyme inhibitors, ARBs Angiotensin receptor blockers
  2. *Fisher’s exact test